Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a multifaceted role in managing type 2 diabetes and promoting weight loss.

FDA Grants Authorization for Mirum Pharmaceuticals' Drug LIVMARLI to Treat Itchy Skin Caused by Bile Buildup in Individuals with Advanced Hereditary Liver Disorder.

Atendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class.

Almirall has entered into an exclusive licensing deal with Eloxx Pharmaceuticals for the use of ZKN-013 in the treatment of uncommon skin conditions.

Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is a medication used for weight loss, type 2 diabetes management, and cardiovascular risk reduction.

BeiGene Granted US Regulatory Nod for TEVIMBRA® to Treat Progressive or Spread Esophageal Cancer Post-Chemotherapy.

Morphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects.

Ionis has disclosed encouraging outcomes from its second-phase trial of ION224, a drug currently being tested which shows promise in addressing NASH/MASH conditions.

Pseudoephedrine Hydrochloride, a small molecule drug, acts as an α-adrenergic receptor agonist, exerting its effects through the stimulation of α-adrenergic receptors.

Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.

Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.

Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.